TABLE 1.
Patient Demographics, Comorbidities, Hospitalization Events, and Outcomes
| Variable | All Patients (n = 26) |
|---|---|
| Age, mean (SD)—yr | 59 (16) |
| Age < 50—no. (%) | 7 (27) |
| Age ≥ 50—no. (%) | 19 (73) |
| Sex—no. (%) | |
| Male | 19 (73) |
| Female | 7 (27) |
| Race/ethnicity—no. (%) | |
| White | 5 (19) |
| African-American | 8 (31) |
| Hispanic/Latino | 5 (19) |
| Asian | 2 (8) |
| Other | 6 (23) |
| Pre-exiting conditions/comorbidities – no. (%) | |
| Hypertension | 14 (54) |
| Obesity (BMI ≥ 30) | 9 (35) |
| Antiplatelet agents/anticoagulants – no. (%) | 6 (23) |
| Atrial fibrillation | 5 (19) |
| Diabetes | 6 (23) |
| Cancer | 4 (15) |
| Smoking | 3 (12) |
| Coronary artery disease | 2 (8) |
| Admitting Characteristics | |
| Admission GCS—median (IQR) | 11 (7.25-14.75) |
| Admission GCS (survivors) | 14 (11.25-15) |
| Admission GCS (mortalities) | 7 (3.75-11.25) |
| Admission NIHSS—median (IQR) | 15 (9.75-20.25) |
| Cranial vascular events—no. (%) | |
| Acute ischemic stroke | 17 (65) |
| LVOa | 15 (58) |
| SVO | 2 (8) |
| Hemorrhagic conversion | 3 (12) |
| Intraparenchymal hemorrhage (hypertensive) | 1 (4) |
| Subarachnoid hemorrhage (aneurysmal) | 1 (4) |
| Hemorrhagic tumor | 2 (8) |
| SDH | 4 (15) |
| CVST | 1 (4) |
| Arterial dissection | 1 (4) |
| In-hospital events and complications—no. (%) | |
| Intubated | 14 (54) |
| ARDS | 8 (31) |
| Pneumonia | 12 (46) |
| Seizure | 1 (4) |
| VTE | 2 (8) |
| Treatment/Intervention—no. (%) | |
| Pharmacological treatment for COVIDb | 16 (62) |
| Chemical VTE prophylaxis | 21 (81) |
| Therapeutic anticoagulation | 5 (19) |
| Intravenous (IV) rtPA given | 6 (23) |
| Endovascular intervention | 10 (38) |
| Mechanical thrombectomy | 9 (35) |
| EVD or ICP monitor | 1 (4) |
| Open neurosurgical intervention | 5 (19) |
| Operative complication (SDH) | 1 (4) |
| Laboratory studies (mean, SD) | |
| D-dimer—ng/mL | 10,289 (23,525) |
| D-dimer among survivors | 3172 (3810) |
| D-dimer among mortalities | 20,963 (35,499) |
| White-cell count—thousand per μL | 9.7 (4.7) |
| Hemoglobin—g/dL | 12.7 (2.4) |
| Platelets—thousand per μL | 257 (120) |
| Ferritin—ng/mL | 922 (947) |
| C-reactive protein—mg/L | 45 (67) |
| Prothrombin time—sec | 13.9 (1.7) |
| Activated partial thromboplastin time—sec | 30.7 (5.0) |
| International normalized ratio | 1.1 (0.2) |
| Disposition—no. (%) | |
| Home | 8 (31) |
| Acute rehabilitation facility | 3 (12) |
| Skilled nursing or intermediate care facility | 3 (12) |
| Outcomes | |
| Death—no. (%) | 12 (46) |
| Discharge GCS—median (IQR) | 14 (13-15) |
| Length of stay—median (IQR) | 9 (4.25-10.75) |
SD, Standard Deviation; BMI, Body Mass Index; GCS, Glasgow Coma Scale; IQR, Interquartile Range; NIHSS, National Institutes of Health Stroke Scale; VTE, Venous Thromboembolism; rtPA, Recombinant Tissue Plasminogen Activator; EVD: External Ventricular Drain; ICP: Intracranial Pressure.
a
Internal carotid artery, basilar artery, intracranial vertebral artery, first segment of the middle cerebral artery (M1), first segment of the anterior cerebral artery (A1), and/or first segment of posterior cerebral artery (P1).
b
Including, but not limited to, hydroxychloroquine, azithromycin, and remdesivir.